Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 14 entries
Sorted by: Best Match Show Resources per page
Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study.

Applied immunohistochemistry & molecular morphology : AIMM

Grushko TA, Filiaci VL, Montag AG, Apushkin M, Gomez MJ, Monovich L, Ramirez NC, Schwab C, Kesterson JP, Seward SM, Method MW, Olopade OI, Fleming GF, Birrer MJ.
PMID: 34224438
Appl Immunohistochem Mol Morphol. 2022 Jan 01;30(1):27-35. doi: 10.1097/PAI.0000000000000949.

We performed a pilot study in anticipation of using long-aged precut formalin-fixed paraffin-embedded tissue sections stored in real-world conditions for translational biomarker studies of topoisomerase 2A (TOP2A), Ki67, and human epidermal growth factor receptor 2 (HER2) in endometrial cancer....

Cite
Grushko TA, Filiaci VL, Montag AG, et al. Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study. Appl Immunohistochem Mol Morphol. 2022;30(1):27-35doi: 10.1097/PAI.0000000000000949.
Grushko, T. A., Filiaci, V. L., Montag, A. G., Apushkin, M., Gomez, M. J., Monovich, L., Ramirez, N. C., Schwab, C., Kesterson, J. P., Seward, S. M., Method, M. W., Olopade, O. I., Fleming, G. F., & Birrer, M. J. (2022). Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study. Applied immunohistochemistry & molecular morphology : AIMM, 30(1), 27-35. https://doi.org/10.1097/PAI.0000000000000949
Grushko, Tatyana A, et al. "Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study." Applied immunohistochemistry & molecular morphology : AIMM vol. 30,1 (2022): 27-35. doi: https://doi.org/10.1097/PAI.0000000000000949
Grushko TA, Filiaci VL, Montag AG, Apushkin M, Gomez MJ, Monovich L, Ramirez NC, Schwab C, Kesterson JP, Seward SM, Method MW, Olopade OI, Fleming GF, Birrer MJ. Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study. Appl Immunohistochem Mol Morphol. 2022 Jan 01;30(1):27-35. doi: 10.1097/PAI.0000000000000949. PMID: 34224438; PMCID: PMC8664981.
Copy Download .nbib Format: NLM
Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062).

Molecular cancer therapeutics

Tewari KS, Sill MW, Monk BJ, Penson RT, Moore DH, Lankes HA, Ramondetta LM, Landrum LM, Randall LM, Oaknin A, Leitao MM, Eisenhauer EL, DiSilvestro P, Van Le L, Pearl ML, Burke JJ, Salani R, Richardson DL, Michael HE, Kindelberger DW, Birrer MJ.
PMID: 32847980
Mol Cancer Ther. 2020 Nov;19(11):2363-2370. doi: 10.1158/1535-7163.MCT-20-0276. Epub 2020 Aug 26.

To isolate circulating tumor cells (CTC) from women with advanced cervical cancer and estimate the impact of CTCs and treatment on overall survival and progression-free survival (PFS). A total of 7.5 mL of whole blood was drawn pre-cycle 1...

Cite
Tewari KS, Sill MW, Monk BJ, et al. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Mol Cancer Ther. 2020;19(11):2363-2370doi: 10.1158/1535-7163.MCT-20-0276.
Tewari, K. S., Sill, M. W., Monk, B. J., Penson, R. T., Moore, D. H., Lankes, H. A., Ramondetta, L. M., Landrum, L. M., Randall, L. M., Oaknin, A., Leitao, M. M., Eisenhauer, E. L., DiSilvestro, P., Van Le, L., Pearl, M. L., Burke, J. J., Salani, R., Richardson, D. L., Michael, H. E., Kindelberger, D. W., & Birrer, M. J. (2020). Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Molecular cancer therapeutics, 19(11), 2363-2370. https://doi.org/10.1158/1535-7163.MCT-20-0276
Tewari, Krishnansu S, et al. "Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062)." Molecular cancer therapeutics vol. 19,11 (2020): 2363-2370. doi: https://doi.org/10.1158/1535-7163.MCT-20-0276
Tewari KS, Sill MW, Monk BJ, Penson RT, Moore DH, Lankes HA, Ramondetta LM, Landrum LM, Randall LM, Oaknin A, Leitao MM, Eisenhauer EL, DiSilvestro P, Van Le L, Pearl ML, Burke JJ, Salani R, Richardson DL, Michael HE, Kindelberger DW, Birrer MJ. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Mol Cancer Ther. 2020 Nov;19(11):2363-2370. doi: 10.1158/1535-7163.MCT-20-0276. Epub 2020 Aug 26. PMID: 32847980; PMCID: PMC7907274.
Copy Download .nbib Format: NLM
Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy.

Oncoimmunology

Facciabene A, De Sanctis F, Pierini S, Reis ES, Balint K, Facciponte J, Rueter J, Kagabu M, Magotti P, Lanitis E, DeAngelis RA, Buckanovich RJ, Song WC, Lambris JD, Coukos G.
PMID: 28932632
Oncoimmunology. 2017 Jun 08;6(9):e1326442. doi: 10.1080/2162402X.2017.1326442. eCollection 2017.

Cancer immunotherapy relies upon the ability of T cells to infiltrate tumors. The endothelium constitutes a barrier between the tumor and effector T cells, and the ability to manipulate local vascular permeability could be translated into effective immunotherapy. Here,...

Cite
Facciabene A, De Sanctis F, Pierini S, et al. Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy. Oncoimmunology. 2017;6(9):e1326442doi: 10.1080/2162402X.2017.1326442.
Facciabene, A., De Sanctis, F., Pierini, S., Reis, E. S., Balint, K., Facciponte, J., Rueter, J., Kagabu, M., Magotti, P., Lanitis, E., DeAngelis, R. A., Buckanovich, R. J., Song, W. C., Lambris, J. D., & Coukos, G. (2017). Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy. Oncoimmunology, 6(9), e1326442. https://doi.org/10.1080/2162402X.2017.1326442
Facciabene, Andrea, et al. "Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy." Oncoimmunology vol. 6,9 (2017): e1326442. doi: https://doi.org/10.1080/2162402X.2017.1326442
Facciabene A, De Sanctis F, Pierini S, Reis ES, Balint K, Facciponte J, Rueter J, Kagabu M, Magotti P, Lanitis E, DeAngelis RA, Buckanovich RJ, Song WC, Lambris JD, Coukos G. Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy. Oncoimmunology. 2017 Jun 08;6(9):e1326442. doi: 10.1080/2162402X.2017.1326442. eCollection 2017. PMID: 28932632; PMCID: PMC5599081.
Copy Download .nbib Format: NLM
Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study.

Frontiers in oncology

Tian CQ, Darcy KM, Krivak TC, Deloia JA, Armstrong D, Davis W, Zhao H, Moysich K, Ambrosone CB.
PMID: 23964347
Front Oncol. 2013 Aug 12;3:206. doi: 10.3389/fonc.2013.00206. eCollection 2013.

PURPOSE: BRCA1/BRCA2 germline mutations appear to enhance the platinum-sensitivity, but little is known about the prognostic relevance of polymorphisms in BRCA1/BRCA2 in epithelial ovarian cancer (EOC). This study evaluated whether common variants of BRCA1/BRCA2 are associated with progression-free survival...

Cite
Tian CQ, Darcy KM, Krivak TC, et al. Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study. Front Oncol. 2013;3:206doi: 10.3389/fonc.2013.00206.
Tian, C. Q., Darcy, K. M., Krivak, T. C., Deloia, J. A., Armstrong, D., Davis, W., Zhao, H., Moysich, K., & Ambrosone, C. B. (2013). Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study. Frontiers in oncology, 3206. https://doi.org/10.3389/fonc.2013.00206
Tian, Chunqiao Q, et al. "Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study." Frontiers in oncology vol. 3 (2013): 206. doi: https://doi.org/10.3389/fonc.2013.00206
Tian CQ, Darcy KM, Krivak TC, Deloia JA, Armstrong D, Davis W, Zhao H, Moysich K, Ambrosone CB. Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study. Front Oncol. 2013 Aug 12;3:206. doi: 10.3389/fonc.2013.00206. eCollection 2013. PMID: 23964347; PMCID: PMC3740480.
Copy Download .nbib Format: NLM
Utility of preoperative ferumoxtran-10 MRI to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN 6671/GOG 0233.

European journal of radiology open

Atri M, Zhang Z, Marques H, Gorelick J, Harisinghani M, Sohaib A, Koh DM, Raman S, Gee M, Choi H, Landrum L, Mannel R, Chuang L, Yu JQ, McCourt CK, Gold M.
PMID: 25774381
Eur J Radiol Open. 2015;2:11-18. doi: 10.1016/j.ejro.2014.11.002.

RATIONALE AND OBJECTIVES: To assess if ferumoxtran-10 (f-10) improves accuracy of MRI to detect lymph node (LN) metastasis in advanced cervical cancer.MATERIALS AND METHODS: F-10 MRI component of an IRB approved HIPAA compliant ACRIN/GOG trial was analyzed. Patients underwent...

Cite
Atri M, Zhang Z, Marques H, et al. Utility of preoperative ferumoxtran-10 MRI to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN 6671/GOG 0233. Eur J Radiol Open. 2015;2:11-18doi: 10.1016/j.ejro.2014.11.002.
Atri, M., Zhang, Z., Marques, H., Gorelick, J., Harisinghani, M., Sohaib, A., Koh, D. M., Raman, S., Gee, M., Choi, H., Landrum, L., Mannel, R., Chuang, L., Yu, J. Q., McCourt, C. K., & Gold, M. (2015). Utility of preoperative ferumoxtran-10 MRI to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN 6671/GOG 0233. European journal of radiology open, 211-18. https://doi.org/10.1016/j.ejro.2014.11.002
Atri, Mostafa, et al. "Utility of preoperative ferumoxtran-10 MRI to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN 6671/GOG 0233." European journal of radiology open vol. 2 (2015): 11-18. doi: https://doi.org/10.1016/j.ejro.2014.11.002
Atri M, Zhang Z, Marques H, Gorelick J, Harisinghani M, Sohaib A, Koh DM, Raman S, Gee M, Choi H, Landrum L, Mannel R, Chuang L, Yu JQ, McCourt CK, Gold M. Utility of preoperative ferumoxtran-10 MRI to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN 6671/GOG 0233. Eur J Radiol Open. 2015;2:11-18. doi: 10.1016/j.ejro.2014.11.002. PMID: 25774381; PMCID: PMC4357172.
Copy Download .nbib Format: NLM
A fast Monte Carlo EM algorithm for estimation in latent class model analysis with an application to assess diagnostic accuracy for cervical neoplasia in women with AGC.

Journal of applied statistics

Kang L, Carter R, Darcy K, Kauderer J, Liao SY.
PMID: 24163493
J Appl Stat. 2013;40(12):2699-2719. doi: 10.1080/02664763.2013.825704.

In this article we use a latent class model (LCM) with prevalence modeled as a function of covariates to assess diagnostic test accuracy in situations where the true disease status is not observed, but observations on three or more...

Cite
Kang L, Carter R, Darcy K, et al. A fast Monte Carlo EM algorithm for estimation in latent class model analysis with an application to assess diagnostic accuracy for cervical neoplasia in women with AGC. J Appl Stat. 2013;40(12):2699-2719doi: 10.1080/02664763.2013.825704.
Kang, L., Carter, R., Darcy, K., Kauderer, J., & Liao, S. Y. (2013). A fast Monte Carlo EM algorithm for estimation in latent class model analysis with an application to assess diagnostic accuracy for cervical neoplasia in women with AGC. Journal of applied statistics, 40(12), 2699-2719. https://doi.org/10.1080/02664763.2013.825704
Kang, Le, et al. "A fast Monte Carlo EM algorithm for estimation in latent class model analysis with an application to assess diagnostic accuracy for cervical neoplasia in women with AGC." Journal of applied statistics vol. 40,12 (2013): 2699-2719. doi: https://doi.org/10.1080/02664763.2013.825704
Kang L, Carter R, Darcy K, Kauderer J, Liao SY. A fast Monte Carlo EM algorithm for estimation in latent class model analysis with an application to assess diagnostic accuracy for cervical neoplasia in women with AGC. J Appl Stat. 2013;40(12):2699-2719. doi: 10.1080/02664763.2013.825704. PMID: 24163493; PMCID: PMC3806648.
Copy Download .nbib Format: NLM
Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative.

European journal of cancer (Oxford, England : 1990)

Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C, Coens C, Pettaway C, Arnold D, Hall E, Marshall E, Sclafani F, Hatcher H, Earl H, Ray-Coquard I, Paul J, Blay JY, Whelan J, Panageas K, Wheatley K, Harrington K, Licitra L, Billingham L, Hensley M, McCabe M, Patel PM, Carvajal R, Wilson R, Glynne-Jones R, McWilliams R, Leyvraz S, Rao S, Nicholson S, Filiaci V, Negrouk A, Lacombe D, Dupont E, Pauporté I, Welch JJ, Law K, Trimble T, Seymour M.
PMID: 25542058
Eur J Cancer. 2015 Feb;51(3):271-81. doi: 10.1016/j.ejca.2014.10.027. Epub 2014 Dec 24.

BACKGROUND: The past three decades have seen rapid improvements in the diagnosis and treatment of most cancers and the most important contributor has been research. Progress in rare cancers has been slower, not least because of the challenges of...

Cite
Bogaerts J, Sydes MR, Keat N, et al. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. Eur J Cancer. 2014;51(3):271-81doi: 10.1016/j.ejca.2014.10.027.
Bogaerts, J., Sydes, M. R., Keat, N., McConnell, A., Benson, A., Ho, A., Roth, A., Fortpied, C., Eng, C., Peckitt, C., Coens, C., Pettaway, C., Arnold, D., Hall, E., Marshall, E., Sclafani, F., Hatcher, H., Earl, H., Ray-Coquard, I., Paul, J., Blay, J. Y., Whelan, J., Panageas, K., Wheatley, K., Harrington, K., Licitra, L., Billingham, L., Hensley, M., McCabe, M., Patel, P. M., Carvajal, R., Wilson, R., Glynne-Jones, R., McWilliams, R., Leyvraz, S., Rao, S., Nicholson, S., Filiaci, V., Negrouk, A., Lacombe, D., Dupont, E., Pauporté, I., Welch, J. J., Law, K., Trimble, T., & Seymour, M. (2015). Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. European journal of cancer (Oxford, England : 1990), 51(3), 271-81. https://doi.org/10.1016/j.ejca.2014.10.027
Bogaerts, Jan, et al. "Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative." European journal of cancer (Oxford, England : 1990) vol. 51,3 (2015): 271-81. doi: https://doi.org/10.1016/j.ejca.2014.10.027
Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C, Coens C, Pettaway C, Arnold D, Hall E, Marshall E, Sclafani F, Hatcher H, Earl H, Ray-Coquard I, Paul J, Blay JY, Whelan J, Panageas K, Wheatley K, Harrington K, Licitra L, Billingham L, Hensley M, McCabe M, Patel PM, Carvajal R, Wilson R, Glynne-Jones R, McWilliams R, Leyvraz S, Rao S, Nicholson S, Filiaci V, Negrouk A, Lacombe D, Dupont E, Pauporté I, Welch JJ, Law K, Trimble T, Seymour M. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. Eur J Cancer. 2015 Feb;51(3):271-81. doi: 10.1016/j.ejca.2014.10.027. Epub 2014 Dec 24. PMID: 25542058; PMCID: PMC4639696.
Copy Download .nbib Format: NLM
The estrogen receptor joins other cancer biomarkers as a predictor of outcome.

Obstetrics and gynecology international

Leslie KK, Thiel KW, Reyes HD, Yang S, Zhang Y, Carlson MJ, Kumar NS, Dai DD.
PMID: 24223042
Obstet Gynecol Int. 2013;2013:479541. doi: 10.1155/2013/479541. Epub 2013 Oct 07.

Endometrial cancer, the most common gynecologic malignancy in the United States, is on the rise, and survival is worse today than 40 years ago. In order to improve the outcomes, better biomarkers that direct the choice of therapy are...

Cite
Leslie KK, Thiel KW, Reyes HD, et al. The estrogen receptor joins other cancer biomarkers as a predictor of outcome. Obstet Gynecol Int. 2013;2013:479541doi: 10.1155/2013/479541.
Leslie, K. K., Thiel, K. W., Reyes, H. D., Yang, S., Zhang, Y., Carlson, M. J., Kumar, N. S., & Dai, D. D. (2013). The estrogen receptor joins other cancer biomarkers as a predictor of outcome. Obstetrics and gynecology international, 2013479541. https://doi.org/10.1155/2013/479541
Leslie, Kimberly K, et al. "The estrogen receptor joins other cancer biomarkers as a predictor of outcome." Obstetrics and gynecology international vol. 2013 (2013): 479541. doi: https://doi.org/10.1155/2013/479541
Leslie KK, Thiel KW, Reyes HD, Yang S, Zhang Y, Carlson MJ, Kumar NS, Dai DD. The estrogen receptor joins other cancer biomarkers as a predictor of outcome. Obstet Gynecol Int. 2013;2013:479541. doi: 10.1155/2013/479541. Epub 2013 Oct 07. PMID: 24223042; PMCID: PMC3816067.
Copy Download .nbib Format: NLM
Quality-of-life results used to endorse changes in standard of care for recurrent platinum-sensitive ovarian cancer.

Expert review of pharmacoeconomics & outcomes research

Chase DM, Wenzel LB, Monk BJ.
PMID: 22812551
Expert Rev Pharmacoecon Outcomes Res. 2012 Jun;12(3):279-81. doi: 10.1586/erp.12.22.

Most women with ovarian cancer will suffer a recurrence. Unfortunately, although initial treatment can lead to undetectable disease, recurrent disease is often more challenging to control. As curative intent is less common after relapse, patients and doctors argue for...

Cite
Chase DM, Wenzel LB, Monk BJ. Quality-of-life results used to endorse changes in standard of care for recurrent platinum-sensitive ovarian cancer. Expert Rev Pharmacoecon Outcomes Res. 2012;12(3):279-81doi: 10.1586/erp.12.22.
Chase, D. M., Wenzel, L. B., & Monk, B. J. (2012). Quality-of-life results used to endorse changes in standard of care for recurrent platinum-sensitive ovarian cancer. Expert review of pharmacoeconomics & outcomes research, 12(3), 279-81. https://doi.org/10.1586/erp.12.22
Chase, Dana M, et al. "Quality-of-life results used to endorse changes in standard of care for recurrent platinum-sensitive ovarian cancer." Expert review of pharmacoeconomics & outcomes research vol. 12,3 (2012): 279-81. doi: https://doi.org/10.1586/erp.12.22
Chase DM, Wenzel LB, Monk BJ. Quality-of-life results used to endorse changes in standard of care for recurrent platinum-sensitive ovarian cancer. Expert Rev Pharmacoecon Outcomes Res. 2012 Jun;12(3):279-81. doi: 10.1586/erp.12.22. PMID: 22812551; PMCID: PMC4920474.
Copy Download .nbib Format: NLM
Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Merritt MA, Strickler HD, Hutson AD, Einstein MH, Rohan TE, Xue X, Sherman ME, Brinton LA, Yu H, Miller DS, Ramirez NC, Lankes HA, Birrer MJ, Huang GS, Gunter MJ.
PMID: 33622671
Cancer Epidemiol Biomarkers Prev. 2021 Apr;30(4):719-726. doi: 10.1158/1055-9965.EPI-20-1613. Epub 2021 Feb 23.

BACKGROUND: The influence of sex hormone and insulin/insulin-like growth factor (IGF) axis signaling on endometrial cancer recurrence is unknown. We evaluated these pathways in a prospective cohort of Gynecologic Oncology Group (GOG)0210 trial endometrial adenocarcinoma patients.METHODS: Stage II-IV patients...

Cite
Merritt MA, Strickler HD, Hutson AD, et al. Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer. Cancer Epidemiol Biomarkers Prev. 2021;30(4):719-726doi: 10.1158/1055-9965.EPI-20-1613.
Merritt, M. A., Strickler, H. D., Hutson, A. D., Einstein, M. H., Rohan, T. E., Xue, X., Sherman, M. E., Brinton, L. A., Yu, H., Miller, D. S., Ramirez, N. C., Lankes, H. A., Birrer, M. J., Huang, G. S., & Gunter, M. J. (2021). Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 30(4), 719-726. https://doi.org/10.1158/1055-9965.EPI-20-1613
Merritt, Melissa A, et al. "Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 30,4 (2021): 719-726. doi: https://doi.org/10.1158/1055-9965.EPI-20-1613
Merritt MA, Strickler HD, Hutson AD, Einstein MH, Rohan TE, Xue X, Sherman ME, Brinton LA, Yu H, Miller DS, Ramirez NC, Lankes HA, Birrer MJ, Huang GS, Gunter MJ. Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer. Cancer Epidemiol Biomarkers Prev. 2021 Apr;30(4):719-726. doi: 10.1158/1055-9965.EPI-20-1613. Epub 2021 Feb 23. PMID: 33622671; PMCID: PMC8026669.
Copy Download .nbib Format: NLM
Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Hensley ML, Enserro D, Hatcher H, Ottevanger PB, Krarup-Hansen A, Blay JY, Fisher C, Moxley KM, Lele SB, Lea JS, Tewari KS, Thaker PH, Zivanovic O, O'Malley DM, Robison K, Miller DS.
PMID: 30289732
J Clin Oncol. 2018 Oct 05;JCO1800454. doi: 10.1200/JCO.18.00454. Epub 2018 Oct 05.

PURPOSE: We conducted a randomized phase III trial to determine whether adjuvant chemotherapy improves survival in women with uterine leiomyosarcoma.METHODS: Women with uterus-confined, high-grade leiomyosarcoma who were confirmed disease free by imaging were randomly assigned to four cycles of...

Cite
Hensley ML, Enserro D, Hatcher H, et al. Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2018;JCO1800454doi: 10.1200/JCO.18.00454.
Hensley, M. L., Enserro, D., Hatcher, H., Ottevanger, P. B., Krarup-Hansen, A., Blay, J. Y., Fisher, C., Moxley, K. M., Lele, S. B., Lea, J. S., Tewari, K. S., Thaker, P. H., Zivanovic, O., O'Malley, D. M., Robison, K., & Miller, D. S. (2018). Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO1800454. https://doi.org/10.1200/JCO.18.00454
Hensley, Martee L, et al. "Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. (2018): JCO1800454. doi: https://doi.org/10.1200/JCO.18.00454
Hensley ML, Enserro D, Hatcher H, Ottevanger PB, Krarup-Hansen A, Blay JY, Fisher C, Moxley KM, Lele SB, Lea JS, Tewari KS, Thaker PH, Zivanovic O, O'Malley DM, Robison K, Miller DS. Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2018 Oct 05;JCO1800454. doi: 10.1200/JCO.18.00454. Epub 2018 Oct 05. PMID: 30289732; PMCID: PMC6241678.
Copy Download .nbib Format: NLM
Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23].

Gynecologic oncology

Olawaiye AB, Java JJ, Krivak TC, Friedlander M, Mutch DG, Glaser G, Geller M, O'Malley DM, Wenham RM, Lee RB, Bodurka DC, Herzog TJ, Bookman MA.
PMID: 30360899
Gynecol Oncol. 2019 Jan;152(1):220. doi: 10.1016/j.ygyno.2018.10.022. Epub 2018 Oct 23.

No abstract available.

Cite
Olawaiye AB, Java JJ, Krivak TC, et al. Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23]. Gynecol Oncol. 2018;152(1):220doi: 10.1016/j.ygyno.2018.10.022.
Olawaiye, A. B., Java, J. J., Krivak, T. C., Friedlander, M., Mutch, D. G., Glaser, G., Geller, M., O'Malley, D. M., Wenham, R. M., Lee, R. B., Bodurka, D. C., Herzog, T. J., & Bookman, M. A. (2019). Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23]. Gynecologic oncology, 152(1), 220. https://doi.org/10.1016/j.ygyno.2018.10.022
Olawaiye, Alexander B, et al. "Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23]." Gynecologic oncology vol. 152,1 (2019): 220. doi: https://doi.org/10.1016/j.ygyno.2018.10.022
Olawaiye AB, Java JJ, Krivak TC, Friedlander M, Mutch DG, Glaser G, Geller M, O'Malley DM, Wenham RM, Lee RB, Bodurka DC, Herzog TJ, Bookman MA. Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23]. Gynecol Oncol. 2019 Jan;152(1):220. doi: 10.1016/j.ygyno.2018.10.022. Epub 2018 Oct 23. PMID: 30360899; PMCID: PMC6321790.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 14 entries